Number of events and Incidence rates of first NL diagnosis during study period in AS patients (n = 8,572) compared to general population comparators (n = 39,639), overall and stratified by status on NL diagnosis prior to study entry.

<p>GPC; general population comparators.</p><p>py; person-years. Person years defined as starting at the date of entry into study (time of AS diagnosis, earliest Jan 1^st 2001) until first of death, emigration, nephrolithiasis diagnosis or end of study (Dec 31^st 2009).</p><p>IQR; interquartile range, IR; incidence rate, CI; confidence interval.</p><p>Number of events and Incidence rates of first NL diagnosis during study period in AS patients (n = 8,572) compared to general population comparators (n = 39,639), overall and stratified by status on NL diagnosis prior to study entry.</p

HRs (95%CI) for all covariates included in initial multivariate Cox regression model.

<p>HRs (95%CI) for all covariates included in initial multivariate Cox regression model.</p

Baseline characteristics of AS cohort and matched general population comparator subjects at study entry.

<p>Baseline characteristics of AS cohort and matched general population comparator subjects at study entry.</p

Flow of AS patients and general population comparators (GPC) prior to and during follow-up, until end of study period.

<p>Flow of AS patients and general population comparators (GPC) prior to and during follow-up, until end of study period.</p

Incidence Rates (95%CI) of NL diagnosis in AS patients and general population comparators (GPC).

<p>Incidence Rates (95%CI) of NL diagnosis in AS patients and general population comparators (GPC).</p

Baseline characteristics and disease activity of patients in the study population according to treatment.

<p>Baseline characteristics and disease activity of patients in the study population according to treatment.</p

Study sample (flow diagram).

<p>Study sample (flow diagram).</p

Utility gain and effectiveness of anti-TNF naïve, anti-TNF switchers and other modes of action (OMA) bDMARDs 6 months follow-up.

<p>Utility gain and effectiveness of anti-TNF naïve, anti-TNF switchers and other modes of action (OMA) bDMARDs 6 months follow-up.</p

Drug survival, stratified by anti-TNF naive, anti-TNF switchers and other modes of action switchers (OMA switchers) in biologic monotherapy.

<p>The graph for the Kaplan-Meier estimated survival has been censored when the number at risk was below 10. The number of patients on a drug at different time points is listed below the figure.</p

Supplemental Material - Predicting Psoriatic Arthritis in Psoriasis Patients – A Swiss Registry Study

Supplemental Material for Predicting Psoriatic Arthritis in Psoriasis Patients – A Swiss Registry Study by Mia-Louise Nielsen, Troels C. Petersen, Lara Valeska Maul, Jacob P. Thyssen, Simon F. Thomsen, Jashin J. Wu, Alexander A. Navarini, Thomas Kündig, Nikhil Yawalkar, Christoph Schlapbach, Wolf-Henning Boehncke, Curdin Conrad, Antonio Cozzio, Raphael Micheroli, Lars Erik Kristensen, Alexander Egeberg, and Julia-Tatjana Maul in Journal of Psoriasis and Psoriatic Arthritis®</p